Condition
Ragweed Allergy
Total Trials
6
Recruiting
0
Active
0
Completed
6
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 6 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Completed6
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05346718Not ApplicableCompleted
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
NCT02396680Completed
Ragweed-SPIRE Follow-On Study
NCT01448603CompletedPrimary
ToleroMune Ragweed Follow up Study
NCT01398137CompletedPrimary
Ragweed Observational Study
NCT01198613Phase 2CompletedPrimary
ToleroMune Ragweed Exposure Chamber Study
NCT01361412Phase 2CompletedPrimary
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
Showing all 6 trials